Three decades of messenger RNA vaccine development

@article{Verbeke2019ThreeDO,
  title={Three decades of messenger RNA vaccine development},
  author={Rein Verbeke and Ine Lentacker and Stefaan C. De Smedt and Heleen Dewitte},
  journal={Nano Today},
  year={2019}
}
Abstract In the early nineties, pioneering steps were taken in the use of mRNA as a therapeutic tool for vaccination. In the following decades, an improved understanding of the mRNA pharmacology, together with novel insights in immunology have positioned mRNA-based technologies as next-generation vaccines. This review outlines the history and current state-of-the-art in mRNA vaccination, while presenting an immunological view on mRNA vaccine development. As such, we highlight the challenges in… 

Figures and Tables from this paper

mRNA vaccines for infectious diseases: principles, delivery and clinical translation
TLDR
The technologies that underlie mRNA vaccines are described, with an emphasis on lipid nanoparticles and other non-viral delivery vehicles, and the pipeline of mRNA vaccines against various infectious disease pathogens is overview.
pDNA and mRNA vaccines
TLDR
The chemistry, pharmacology, formulation, and process development of plasmid DNA and messenger RNA vaccines is summarized and the outlook for nucleic acid–based vaccines in the context of rapid pandemic response is offered.
Recent advances in mRNA vaccine technology.
TLDR
This review summarizes the most important developments in mRNA vaccines from the past few years and discusses the challenges and future directions for the field.
HIV mRNA Vaccines—Progress and Future Paths
TLDR
This review discusses mRNA-based approaches for the generation of prophylactic and therapeutic vaccines to HIV, and examines the special immunological hurdles for a vaccine to elicit broadly neutralizing antibodies and effective T cell responses to HIV.
Self-assembled mRNA vaccines
TLDR
Design and self-assembly of mRNA vaccines are discussed, showing tremendous promise in the COVID-19 vaccine race, and have pushed the boundaries of gene therapy.
The dawn of mRNA vaccines: The COVID-19 case
TLDR
This review digs deeper into the scientific breakthroughs of the last decades that laid the foundations for the rapid rise of mRNA vaccines during the COVID-19 pandemic and points out which unknowns remain that require further investigation and possibly, optimization in future mRNA vaccine development.
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
TLDR
This manuscript timely reviews the most advanced mRNA-LNP vaccines that have just been approved for emergency use and are in clinical trials, with a focus on the remarkable development of several COVID-19 vaccines, faster than any other vaccine in history.
From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape
TLDR
The mRNA vaccine structure in general, the different delivery systems, the immune response, and the recent clinical trials for mRNA vaccines are presented, and a snapshot of the different leading mRNA vaccine developers, challenges, and future prospects are illustrated.
mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection
TLDR
In this review, details regarding the optimization of mRNA vaccines, and the underlying biological mechanisms of this form of vaccines are summarized and applications of mRNA vaccine applications in some infectious diseases and cancers are introduced.
The mRNA vaccine revolution is the dividend from decades of basic science research.
The 2021 Lasker-DeBakey Clinical Medical Research Award honors Drs. Katalin Karikó and Drew Weissman for key contributions that allowed mRNA vaccines to become reality. The utility and effectiveness
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 232 REFERENCES
A novel, disruptive vaccination technology
TLDR
Initial clinical experiences suggest that the preclinical immunogenicity of RNActive® could be successfully translated to humans and protect against lethal challenges with a variety of different influenza strains in preclinical models.
mRNA vaccines — a new era in vaccinology
TLDR
A detailed overview of mRNA vaccines is provided and future directions and challenges in advancing this promising vaccine platform to widespread therapeutic use are considered.
Developing mRNA-vaccine technologies
TLDR
Based on in situ protein expression, mRNA vaccines are capable of inducing a balanced immune response comprising both cellular and humoral immunity while not subject to MHC haplotype restriction and are an intrinsically safe vector.
Tools for translation: non-viral materials for therapeutic mRNA delivery
In recent years, messenger RNA (mRNA) has come into the spotlight as a versatile therapeutic with the potential to prevent and treat a staggering range of diseases. Billions of dollars have been
mRNA: Fulfilling the Promise of Gene Therapy.
  • D. Weissman, K. Karikó
  • Biology, Medicine
    Molecular therapy : the journal of the American Society of Gene Therapy
  • 2015
TLDR
An alternative method for generating nonimmunogenic IVT mRNA that avoids the use of modified nucleosides is reported and it is demonstrated that sequence engineering of the mRNA and purifying it with high performance liquid chromatography are sufficient to avoid immune activation and to achieve high levels of translation of the encoded protein.
mRNA-based therapeutics — developing a new class of drugs
TLDR
This Review provides a comprehensive overview of the current state of mRNA-based drug technologies and their applications, and discusses the key challenges and opportunities in developing these into a new class of drugs.
How mRNA therapeutics are entering the monoclonal antibody field
TLDR
The potential of mRNA-based approaches to solve several of the issues associated with antibodies produced and delivered in protein format are highlighted and key hurdles that mRNA- based approaches still need to take are identified to fulfill this potential and ultimately replace the current protein antibody format.
mRNA as novel technology for passive immunotherapy
TLDR
Based on great progress in understanding and manipulating mRNA properties, efficacy data in various models have now demonstrated that IVT mRNA constitutes a potent and flexible platform technology.
mRNA therapeutics deliver a hopeful message
TLDR
The different synthetic mRNA platforms, their production and purification, strategies to tackle the inherent innate immunogenicity of synthetic mRNA, the recent progress in the development of nanoformulations for the in vivo delivery of mRNA, as well as the efficacy and safety of mRNA therapeutics in recent clinical trials are described.
Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses
New vaccine platforms are needed to address the time gap between pathogen emergence and vaccine licensure. RNA-based vaccines are an attractive candidate for this role: they are safe, are produced
...
1
2
3
4
5
...